What a ‘norepinephrine drug’ can and can’t do
Suppose the selective norepinephrine deficit is real, and you take a drug that raises norepinephrine signalling — an NRI like atomoxetine, or a dual dopamine/norepinephrine reuptake inhibitor like solriamfetol. What should you expect?
The answer follows from what the deficit correlates with. In the source study, the norepinephrine pathway tracked handgrip endurance and fatigue scores — motor output and global health perception — and the largest reduction was in the PEM subgroup (Aregawi et al. (2026)).
Reasonable to expect (modestly): - Fatigue / effort-motor endurance — the strongest, if still cross-sectional, signal. - Post-exertional malaise — plausible; the deficit tracks PEM status.
Possible but weaker: unrefreshing sleep and arousal stability — the role of norepinephrine in sleep substates is animal evidence (Osorio-Forero et al. (2021)).
Weak or absent signal in the source study (a null in a small sample does not prove there is no effect): - Orthostatic intolerance / POTS — no relationship was found with orthostatic blood pressure or heart rate. - Mood and anxiety — no correlation found. - Pain — no correlation found, though a separate review links norepinephrine to descending pain control. - Cognition — no correlation found. - Muscle soreness — a different mechanism, and not lactate-driven. - Lactate changes — noradrenergic signalling raises acute lactate, so a deficit would more plausibly lower it than raise it.
The trap: masking. Stimulant-type drugs that raise arousal and effort drive can make you feel more capable without restoring energy — so you do more and crash harder. This masking hazard is a plausible clinical concern, but it has not been measured in a controlled ME/CFS trial; treat it as a caution to watch, not an established fact.
And the hard limit: no ME/CFS trial of these drugs has used PEM as an endpoint, so every “expect” above is an inference from correlation, not a measured outcome. Human data otherwise come from other conditions — orthostatic hypotension, narcolepsy, MS, fibromyalgia. The one ME/CFS trial of these drugs, of solriamfetol, improved fatigue and executive function but did not measure PEM (Young et al. (2025)). Amantadine, an NMDA antagonist with indirect dopaminergic activity, failed to help MS fatigue (Cruccioli et al. (2026)).
Everything here rests on a single, unreplicated CSF study of 16 patients (Aregawi et al. (2026)). This is not medical advice. Any trial of these drugs belongs with a clinician, with pacing and baseline autonomic checks.